Prostatype Q1: The launch is advancing despite limited access to growth capital - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Prostatype Q1: The launch is advancing despite limited access to growth capital - Redeye

{newsItem.title}

Prostatype recorded SEK 0.4m in sales in the first quarter. During this period, Prostatype continues to progress in the US, where the next step is to sign a certified partner. In Europe, the company has secured partners in the Nordics and the Iberian peninsula (Spain and Portugal). Prostatype closed a new share issue amounting to SEK 24m before costs in May. We are updating our base case reflecting the recent right issue and an updated outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/913537/prostatype-q1-the-launch-is-advancing-despite-limited-access-to-growth-capital?utm_source=finwire&utm_medium=RSS

Nyheter om Prostatype Genomics

Läses av andra just nu

Om aktien Prostatype Genomics

Senaste nytt